News

The director emeritus of the Lou Ruvo Center for Brain Health at Cleveland Clinic and vice chair of the Department of Brain Health at the University of Nevada-Las Vegas discussed the role repurposed agents play in Alzheimer disease development.

Researchers noted that further examinations are needed of the genetic heterogeneity depression syndromes to test for causal relationships between distinct subtypes of depression and Alzheimer disease.

The data support and extend the safe use of combination treatment with rimegepant and CGRP monoclonal antibodies in migraine that was initially reported in 2 earlier cases.

Neurology News Network for the week ending August 22, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending August 21, 2020.

Noninvasive neuromodulation with TAPS is a safe and effective tool that offers particular utility in the age of COVID-19 when other treatment options may be less accessible.

The chief research officer and epilepsy specialist at Cleveland Clinic detailed the patient-centered pros and cons associated with epilepsy surgery, as well as the stigmas related to it.

Neurological deterioration was observed in about 1 of 7 patients who received in-hospital care for acute ischemic stroke or transient ischemic attack.

Novartis’ anti-CD20 monoclonal antibody ofatumumab (Kesimpta) is administered once monthly at home, and is expected to be available for those with multiple sclerosis as early as September 2020.

Qutenza becomes the first topical treatment with a TRPV1 agonist indicated for the treatment of neuropathic pain associated with diabetic peripheral neuropathy.

The co-director of the Neurological Clinical Research Institute at Massachusetts General Hospital offered her perspective on the expected developments for ALS care in next few years, and where AMX0035 might fit in that landscape.

The presence of laryngeal movement disorders—identified in 93% of the MSA group—may serve as a diagnostic biomarker of MSA independent of phenotype, disease duration, or patient age.

Hubert Fernandez, MD, the director of the Center for Neurological Restoration at Cleveland Clinic, detailed the importance of raising awareness for Parkinson disease and the strides made in research.

The chief research officer and epilepsy specialist at Cleveland Clinic detailed her most recent findings on the cost-effectiveness of epilepsy surgery for drug-resistant temporal lobe epilepsy.

The head of the Non-Invasive Brain Stimulation Lab at the Santa Lucia Foundation spoke to the challenges in Alzheimer research, biomarkers, and the next steps for rotigotine in this population.

Researchers noted that the development of a simple scale focused on abnormalities in dementia with Lewy bodies may help to further incorporate the EEG in clinical decision-making.

For both surgical and nonsurgical patients, delirium may play a role as an independent risk factor for long-term cognitive decline, implying that the reduction of the former may improve the latter.

The director of the Lou Ruvo Center for Brain Health and neurologist at Cleveland Clinic discussed the potential of aducanumab and the amyloid theory in patients with Alzheimer disease.

The goal is to improve the delivery of care and outcomes for patients with epilepsy as they transition from pediatric to adult care settings, where there is often less oversight.

A follow-up cohort study demonstrates that educating optometrists on the importance and utility of a validated migraine screening tool is a simple, low-time investment intervention, the researchers stated.

The vice president of science and medical at Dreem discussed how the company’s headband device stacked up against polysomnography for sleep monitoring.

The head of the Non-Invasive Brain Stimulation Lab at the Santa Lucia Foundation discussed the phase 2 findings and offered takeaways on rotigotine’s possible place in Alzheimer treatment.

Endovascular treatment may benefit patients with emergent large vessel occlusion and target mismatch profiles regardless of the time from onset.

The subcutaneous injection is indicated in patients with anti-aquaporin-4 antibody positive NMOSD.

Patients with refractory temporal lobe epilepsy may be more inclined to opt for surgery when they understand the long-term cost effectiveness, as well as rates of increased seizure freedom and reduced seizure relapses.

Neurology News Network for the week ending August 15, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending August 14, 2020.

Recent news that the FDA has granted the fastest possible review for Biogen’s Alzheimer disease treatment aducanumab may be indicative of the agency’s increasing confidence in the drug.